Učitavanje...
Bortezomib Reduces Preexisting Antibodies to Recombinant Immunotoxins in Mice()
Recombinant immunotoxin (RIT) therapy is limited in patients by neutralizing antibody responses. Ninety percent of patients with normal immune systems make neutralizing antibodies after one cycle of RIT, preventing repeated dosing. Furthermore, some patients have preexisting antibodies from environm...
Spremljeno u:
| Izdano u: | J Immunol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4323725/ https://ncbi.nlm.nih.gov/pubmed/25560410 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1402324 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|